Bryter Health and Pharma

A great night at the?#BOBIawards?with?Bryter?picking up the Best Customer Insight award for our work with Alzheimer's Society! ?? ??. A fantastic achievement for the team with this being one of ten winning or shortlisted studies at the BOBIs in the last seven years. We were also shortlisted this year for Best Use of Innovation with Bayer UK. Thanks to the?BHBIA team,?to Kelly West and Wilf Iliffe?for hosting with their usual aplomb,?to Survey Healthcare Global as sponsors of this award, and to all those involved in the submission, our colleagues, clients, and partners. A big well done to all others shortlisted and picking up awards last night #BOBIs?#teamwork?#insight?#impact

Energized from a great few days at Intellus Worldwide?in Charlotte, NC with Benjamin Gibbons. Thank you to everyone who came to our talks and stopped by the Bryter booth. Big thanks for organizing a great conference?Heidi Boyle?and for all the help throughout?Paul Evans! That’s a wrap!?

A great first day at Intellus Worldwide with some engaging conversations on all things omnichannel! Great to present our paper and lead discussions on the role that insights (and AI!) will play for pharma channel marketing this in the years ahead. Get in touch to learn more or for those in Charlotte we'll be in and around our booth again today and tomorrow. ??Bryter Health and Pharma - Booth #609 ?? www.bryter-global.com

Consumer attitudes to health have changed in interesting ways between 2021 and 2024, due to a number of factors. To better understand this, Bryter undertook a survey of US consumers to ask them about their health goals, and which products, digital tools & services they are using to meet those goals. Ultimately to understand if attitudes and behaviors have changed in the last three years and if this, in turn, is impacting the types of products they are buying. Here's another sneak peek of our report on the topic... Find the full report on our website: https://lnkd.in/eKTaJvTy

2021 marked the end of lockdown and a return to the 'new normal'. But how have consumer attitudes to health changed between 2021 and 2024? To better understand this, Bryter undertook a survey of US consumers to ask them about their health goals, and which products, digital tools & services they are using to meet those goals. Ultimately to understand if attitudes and behaviors have changed in the last three years and if this, in turn, is impacting the types of products they are buying. Here's sneak peek of our report on the topic... Find the full report on our website: https://lnkd.in/eKTaJvTy

With UK survival rates lower than other developed counties, new innovations are needed to improve the quality of health services, patient experiences and clinical outcomes. Bryter asked senior UK oncologists to reflect on the innovations they consider had the most impact on their patient care in 2024, as well as those they are most looking forward to in 2025. Key themes based on feedback include: ? Continued focus on personalised or precision medicine; with expanded usage of targeted immunotherapies and antibody-drug conjugates (ADCs) to enhance patient outcomes. ? The use of Artificial Intelligence (AI) with its application set to speed up and enhance the accuracy of diagnostics, driving earlier identification of cancer patients. New AI trials, such as the recent world-leading breast cancer screening programme, demonstrate the continued potential growth of AI in oncology. ? Advancements in cancer diagnostics, such as enhanced Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) imaging, allow better surgical precision, earlier diagnosis, and more timely treatment decision making. ? Biomarker testing continues to expand and evolve, ensuring the individualisation of therapy. Liquid biopsies are being used to extend access to testing (and subsequently targeted treatments). ? Other significant areas of development include cancer vaccines and radioligand therapies. However, the adoption of these innovations is impacted by continued pressures on NHS capacity, funding, and staffing. Details on how the government will address this are expected in a new National Cancer Plan later this year. It will be interesting to see which innovations will be pushed to improve quality and efficiency of cancer care pathways and how potential obstacles are alleviated. #oncology #NHS

In late 2023, Bryter spoke to UK consumers about the role sport tech played in their lives. Since then, the landscape has shifted rapidly. In our latest report, Bryter's Anzie H. explores what's changed. Results from our 2025 study indicate that while sports participation levels haven't changed, attitudes towards sport tech are shifting. #sport #sporttech #sporttechmarket https://lnkd.in/eMCQ63qu

With UK survival rates lower than other developed counties, new innovations are needed to improve the quality of health services, patient experiences and clinical outcomes. Bryter asked senior UK oncologists to reflect on the innovations they consider had the most impact on their patient care in 2024, as well as those they are most looking forward to in 2025. Key themes based on feedback include: ? Continued focus on personalised or precision medicine; with expanded usage of targeted immunotherapies and antibody-drug conjugates (ADCs) to enhance patient outcomes. ? The use of Artificial Intelligence (AI) with its application set to speed up and enhance the accuracy of diagnostics, driving earlier identification of cancer patients. New AI trials, such as the recent world-leading breast cancer screening programme, demonstrate the continued potential growth of AI in oncology. ? Advancements in cancer diagnostics, such as enhanced Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) imaging, allow better surgical precision, earlier diagnosis, and more timely treatment decision making. ? Biomarker testing continues to expand and evolve, ensuring the individualisation of therapy. Liquid biopsies are being used to extend access to testing (and subsequently targeted treatments). ? Other significant areas of development include cancer vaccines and radioligand therapies. However, the adoption of these innovations is impacted by continued pressures on NHS capacity, funding, and staffing. Details on how the government will address this are expected in a new National Cancer Plan later this year. It will be interesting to see which innovations will be pushed to improve quality and efficiency of cancer care pathways and how potential obstacles are alleviated. #oncology #NHS

With UK survival rates lower than other developed counties, new innovations are needed to improve the quality of health services, patient experiences and clinical outcomes. Bryter asked senior UK oncologists to reflect on the innovations they consider had the most impact on their patient care in 2024, as well as those they are most looking forward to in 2025. Key themes based on feedback include: ? Continued focus on personalised or precision medicine; with expanded usage of targeted immunotherapies and antibody-drug conjugates (ADCs) to enhance patient outcomes. ? The use of Artificial Intelligence (AI) with its application set to speed up and enhance the accuracy of diagnostics, driving earlier identification of cancer patients. New AI trials, such as the recent world-leading breast cancer screening programme, demonstrate the continued potential growth of AI in oncology. ? Advancements in cancer diagnostics, such as enhanced Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) imaging, allow better surgical precision, earlier diagnosis, and more timely treatment decision making. ? Biomarker testing continues to expand and evolve, ensuring the individualisation of therapy. Liquid biopsies are being used to extend access to testing (and subsequently targeted treatments). ? Other significant areas of development include cancer vaccines and radioligand therapies. However, the adoption of these innovations is impacted by continued pressures on NHS capacity, funding, and staffing. Details on how the government will address this are expected in a new National Cancer Plan later this year. It will be interesting to see which innovations will be pushed to improve quality and efficiency of cancer care pathways and how potential obstacles are alleviated. #oncology #NHS

New Bryter publication with CSL Behring and Immune Deficiency Foundation highlights the benefits of SCIG over IVIG for immunodeficiency patients ?? We are excited to announce the publication of our study in Allergy, Asthma & Clinical Immunology, where we explored how infusion methods—subcutaneous immunoglobulin (SCIG) vs. intravenous immunoglobulin (IVIG)—impact quality of life and treatment satisfaction for patients with primary and secondary immunodeficiencies. Here are the key takeaways: ? Higher IG-Specific Quality of Life with SCIG: Patients using SCIG reported significantly better scores on the Life Quality Index (LQI). SCIG patients scored higher in areas related to convenience and reduced interference with daily life. ? Time Efficiency: SCIG infusions were much faster than IVIG, with shorter pre-infusion, infusion, and post-infusion times. ? Less Disruption to Work/School: Only 11% of SCIG patients reported missing work or school due to treatment, compared to 28% of IVIG patients. ? Patient Autonomy: SCIG’s flexibility and home-based self-administration were major factors contributing to higher satisfaction. While both methods are effective, SCIG offers advantages for patients seeking greater convenience and minimal disruption to their daily lives. This research highlights the importance of tailoring treatment options to individual patient needs. ?? Read the full study here: https://lnkd.in/ed42X486 What are your thoughts on the growing use of SCIG in immunodeficiency care? Let’s discuss! ?? #Immunology #HealthcareResearch #PatientCare #QualityOfLife?